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Abstract
Background:  Monoamine oxidase A (MAO-A), a mitochondrial enzyme that degrades
monoamines including neurotransmitters, is highly expressed in basal cells of the normal human
prostatic epithelium and in poorly differentiated (Gleason grades 4 and 5), aggressive prostate
cancer (PCa). Clorgyline, an MAO-A inhibitor, induces secretory differentiation of normal prostate
cells. We examined the effects of clorgyline on the transcriptional program of epithelial cells
cultured from high grade PCa (E-CA).
Methods: We systematically assessed gene expression changes induced by clorgyline in E-CA cells
using high-density oligonucleotide microarrays. Genes differentially expressed in treated and
control cells were identified by Significance Analysis of Microarrays. Expression of genes of interest
was validated by quantitative real-time polymerase chain reaction.
Results: The expression of 156 genes was significantly increased by clorgyline at all time points
over the time course of 6 – 96 hr identified by Significance Analysis of Microarrays (SAM). The list
is enriched with genes repressed in 7 of 12 oncogenic pathway signatures compiled from the
literature. In addition, genes downregulated ≥ 2-fold by clorgyline were significantly enriched with
those upregulated by key oncogenes including beta-catenin and ERBB2, indicating an anti-oncogenic
effect of clorgyline. Another striking effect of clorgyline was the induction of androgen receptor
(AR) and classic AR target genes such as prostate-specific antigen together with other secretory
epithelial cell-specific genes, suggesting that clorgyline promotes differentiation of cancer cells.
Moreover, clorgyline downregulated EZH2, a critical component of the Polycomb Group (PcG)
complex that represses the expression of differentiation-related genes. Indeed, many genes in the
PcG repression signature that predicts PCa outcome were upregulated by clorgyline, suggesting
that the differentiation-promoting effect of clorgyline may be mediated by its downregulation of
EZH2.
Conclusion:  Our results suggest that inhibitors of MAO-A, already in clinical use to treat
depression, may have potential application as therapeutic PCa drugs by inhibiting oncogenic
pathway activity and promoting differentiation.
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Background
Adenocarcinomas of the prostate are categorized accord-
ing to the Gleason grading system, which consists of five
histological patterns based on microscopic tumor archi-
tecture [1]. Numerous studies have shown a correlation
between Gleason grade and disease outcome [2]. In par-
ticular, the percentage of the largest (index) cancer that is
Gleason grade 4 and/or 5 (poorly differentiated) has
strong predictive value [2,3]. Specifically, cancers com-
posed entirely of Gleason grade 3 (well-differentiated)
have a > 95% chance of being cured by surgery. In con-
trast, each increase of 10% in the percent of the tumor
classified as grade 4/5 at the time of surgery leads to a 10%
increase in the failure rate as measured by detectable and
rising serum prostate specific antigen (PSA), a biomarker
of prostate cancer (PCa). Therefore, understanding the
molecular basis of the aggressive behavior of grade 4/5
cancer is of considerable clinical relevance. Despite the
accumulating knowledge about the biology of PCa, the
molecular machineries that differ between grade 3 and 4/
5 cancers and mark a critical change from curable to lethal
are largely unknown.
Monoamine oxidase A (MAO-A) is a mitochondrial
enzyme that degrades monoamine neurotransmitters
including 5-hydroxytryptamine (5-HT, or serotonin) and
norepinephrine [4]. It is one of the most highly over-
expressed genes in Gleason grade 4/5 PCa compared to
grade 3 cancer [5], raising the possibility that activity of
this enzyme is a key factor in the increased lethality of
high grade PCa [2,3]. MAO-A is also highly expressed in
basal cells of the normal prostatic epithelium. Using pri-
mary cultures of normal human prostatic epithelial cells
as a model of basal cells, we showed that MAO-A prevents
their differentiation into secretory epithelial cells [6], con-
sistent with an anti-differentiation role of MAO-A in neu-
ral stem cells [7]. Specifically, under differentiation-
promoting culture conditions, clorgyline, an irreversible
MAO-A inhibitor [8], induced expression of androgen
receptor (AR), a hallmark of secretory epithelial cells, and
repressed expression of cytokeratin 14, a basal cell marker
[6]. It also induced secretory epithelial cell-like morphol-
ogy [6]. Our results suggest that increased expression of
MAO-A in high grade PCa may be an important contribu-
tor to its poorly differentiated and aggressive phenotype.
In our recent study using a cohort of high grade cancers,
increased expression of MAO-A correlated with an
increased percentage of Gleason grade 4 and 5 cancer in
the largest (index) tumor and with pre-operative serum
PSA levels [9], two powerful prognostic factors for recur-
rence of PCa after radical prostatectomy [3,10].
The above findings suggest that inhibition of MAO-A
might restore differentiation and reverse the aggressive
behavior of high grade PCa. The functions of MAO-A in
the nervous system have been extensively studied [4] and
its inhibitors are currently used to treat several neurologi-
cal diseases such as depression [11], therefore, insights
into the effects of MAO-A inhibitors on PCa could rapidly
lead to clinical trials to test therapeutic activity of such
inhibitors. In this study, we examined the gene expression
changes in primary cultures of cancer cells derived from
high grade surgical specimens (E-CA cells) in response to
clorgyline treatment, and identified two major effects of
clorgyline on PCa cells.
Methods
Isolation, culture, and treatment of prostatic cancer cells
Primary cultures of human prostatic cancer cells, E-CA-88
and -90, were established from histologically confirmed
cancer tissues in radical prostatectomy specimens as pre-
viously described [12]. All human subject studies were
done in compliance with the Helsinki Declaration and
reviewed by Institutional Review Board at Stanford Uni-
versity. E-CA-88 was derived from cancer composed of
80% Gleason grade 4 and 20% Gleason grade 3, and E-
CA-90 from cancer of 100% Gleason grade 4. The patients
did not have prior chemical, hormonal, or radiation ther-
apy. Primary cultures were passaged three times, then cells
were grown in Complete MCDB 105 (Sigma-Aldrich, St.
Louis, MO) until 50% confluent as previously described
[12]. At time zero, control cells were fed Complete PFMR-
4A [12] without epidermal growth factor (EGF) and with
10 nM 1,25-dihydroxyvitamin D3, 1 μM all-trans retinoic
acid, 1 ng/ml transforming growth factor (TGF)-β1, and 1
nM R1881 (designated as "VRTR"). This "differentiation-
promoting" medium was previously shown to be essential
for the differentiation of normal prostatic cells in
response to clorgyline [6]. Experimental cells were fed the
same medium as control cells except that 1 μM clorgyline
was added. Total RNA was isolated from control and clor-
gyline-treated cells at 6, 24, and 96 hr after treatment as
previously described [6].
1,25-dihydroxyvitamin D3 (Biomol International, Ply-
mouth Meeting, PA) was prepared at 10 mM in DMSO.
TGF-β1 (Preprotech, Inc., Rocky Hill, NJ) was prepared in
10 mM citric acid (pH 3.0) at 100 μg/ml. All-trans retinoic
acid (Sigma-Aldrich) was prepared in DMSO at 1 mM.
Clorgyline (Sigma) was prepared at 100 mM in water. The
synthetic androgen R1881 (Perkin Elmer, Waltham, MA)
was prepared in ethanol at 10 μM.
Oligonucleotide microarray hybridizations
Fluorescently-labeled cDNA probes were prepared from
50 to 70 μg total RNA by reverse transcription using an
Oligo dT primer 50-TTTTTTTTTTTTTTTT-30 (Qiagen,
Valencia, CA) and indirect amino-allyl labeling as
described previously [13]. Cy5-labeled probes from con-
trol or clorgyline-treated cells for each time point wereBMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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mixed with Cy3-labeled probe from Universal Human
Reference RNA (Stratagene, La Jolla, CA) and hybridized
overnight at 65°C to spotted oligonucleotide microarrays
with 44,544 70 mer elements (Stanford Functional
Genomics Facility). Microarray slides were then washed to
remove unbound probe and scanned with a GenePix
4000B scanner (Axon Instruments, Inc., Union City, CA).
Data processing and analysis
The acquired fluorescence intensities for each fluoroprobe
were analyzed with GenePix Pro 5.0 software (Axon
Instruments, Inc.). Spots of poor quality were removed
from further analysis by visual inspection. Data files con-
taining fluorescence ratios were entered into the Stanford
Microarray Database (SMD) where biological data were
associated with fluorescence ratios and genes were
selected for further analysis [14]. Data were retrieved only
from spots with a signal intensity >150% above back-
ground in either Cy5- or Cy3-channels from SMD. Genes
with potentially significant changes in expression in
response to clorgyline were identified using the signifi-
cance analysis of microarrays (SAM) procedure [15].
Common genes among different data sets were identified
using Microsoft Excel. The genes and arrays in the result-
ing data tables were ordered by their patterns of gene
expression and visualized using Treeview software http://
rana.lbl.gov/EisenSoftware.htm. The Chi-square test was
used to determine gene enrichment. All data have been
deposited into Gene Expression Omnibus (GEO) with
accession number GSE17167.
Quantitative real-time reverse transcription polymerase 
chain reaction (qRT-PCR)
Total RNA from control and treated cells was reverse tran-
scribed as described above. cDNA product was then mixed
with SYBR®  GreenER™ qPCR SuperMix (Invitrogen,
Carlsbad, CA) and primers of choice in the subsequent
PCR reaction using an MxPro3000 real-time PCR Detec-
tion System (Stratagene) according to the manufacture's
instructions. Each reaction was done in triplicate to mini-
mize the experimental variations (standard deviation was
calculated for each reaction). Transcript levels of GAPDH
were assayed simultaneously with each of the twenty
selected genes as an internal control to normalize tran-
script levels in control and treated cells. The primer
sequences used were listed in Additional file 1.
Proliferation assay
Cells were grown in Complete PFMR-4A without EGF and
supplemented with VRTR plus 1 μm clorgyline for 6, 24,
or 96 hr. Control cells were grown in Complete PFMR-4A
in parallel. Cells were then detached using TrypLE Express
(Invitrogen) and seeded in Complete MCDB 105 medium
at a density of 500 cells/60-mm collagen-coated dish.
After 10 days, cells were fixed with 10% formalin and
stained with 0.1% crystal violet. The number of cells on
each plate was counted under a microscope. Triplicate
plates were set up for each condition to minimize experi-
mental variations. The statistical significance of the differ-
ences in cell numbers was assessed by t-test.
Results
Significance analysis of microarrays (SAM) identifies genes 
upregulated by clorgyline
A primary culture of epithelial cells (E-CA-88) derived
from a high grade adenocarcinoma of the prostate was
treated with diluent or 1 μM of clorgyline, an irreversible
inhibitor of MAO-A. The concentration of 1 μM was cho-
sen because previous studies have shown that it is an effec-
tive dose to elicit a variety of effects in cultured animal
cells [16-18]. Our earlier study using normal primary pro-
static basal epithelial cells also showed that 1 μM clor-
gyline induced secretory differentiation [6]. In normal
cells, secretory differentiation occurred by 96 hr after clor-
gyline treatment. Therefore, the three time points chosen
for profiling are sufficient to capture the gene expression
changes elicited by clorgyline at early and late stages. Total
RNA was isolated at 6, 24 and 96 hr. Gene expression pro-
filing was carried out on high-density oligonucleotide
microarrays.
To identify genes differentially expressed in control vs.
clorgyline-treated cells across the entire time course of 96
hr, we performed SAM using data from 37,340 clones
whose signal intensities were >150% above background
in either Cy5- and Cy3-channels. Two hundred and six-
teen clones representing 156 unique genes were selected
with a false positive rate of 5% (Figure 1A). A complete list
of the gene names (Additional data file 2) and the raw
data are available at http://www.stanford.edu/
~hongjuan/MAO-A. All of the 156 genes were upregulated
in response to clorgyline whereas no genes downregulated
by clorgyline were selected by SAM (Figure 1A and 1B).
The absence of significantly downregulated genes by this
analysis suggests that down regulation of genes by clor-
gyline was not expanding throughout the period of treat-
ment, but rather occurred at one or two time points. In
total, expression of 4026, 5606, and 2299 genes increased
and 3576, 2486, and 597 genes decreased at least 2-fold
in response to clorgyline at 6, 24, or 96 hr time points,
respectively. A complete list of the gene names and their
expression changes are available at http://www.stan
ford.edu/~hongjuan/MAO-A (Additional data file 3).
The changes in expression of the top 10 genes selected by
SAM were validated by qRT-PCR in E-CA-88 cells. All 10
genes showed increased expression in clorgyline-treated
compared to control cells across all time points measured
(Figure 2A). The average fold-changes measured by qRT-BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
Page 4 of 15
(page number not for citation purposes)
Identification of genes whose expression significantly changed by clorgyline across the entire time course of 96 hr in E-CA-88  cells using Statistical Analysis of Microarrays (SAM) Figure 1
Identification of genes whose expression significantly changed by clorgyline across the entire time course of 96 
hr in E-CA-88 cells using Statistical Analysis of Microarrays (SAM). (A) SAM plot selected 216 clones (red dots) rep-
resenting 156 unique named genes significantly upregulated at a false positive rate of 5%. (B) Gene expression profiles of these 
216 clones across the time course. Each row represents a gene and each column represents a sample of control (C) or treated 
(T) cells. The order of the genes displayed is based on their ranks of significance determined by SAM. Positions of genes 
repressed by beta-catenin overexpression are indicated. The degree of color saturation corresponding to the ratio of gene 
expression is shown at the bottom of the image. Red indicates higher expression in experimental samples compared to the 
common reference sample, and green indicates lower expression.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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Validation of gene expression changes of the top 10 genes in E-CA-88 cells selected by SAM using qRT-PCR Figure 2
Validation of gene expression changes of the top 10 genes in E-CA-88 cells selected by SAM using qRT-PCR. 
(A) The relative expression levels of the top 10 genes in clorgyline-treated cells compared to control determined by qRT-PCR. 
(B) Average gene expression changes determined by qRT-PCR compared to those calculated by SAM. For qPCR, fold changes 
at each time point were calculated first and the three fold changes were averaged. For SAM, the average of gene expression 
across the three time points for treated (T) and control (C) was calculated first and then the fold change was determined as T/
C.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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PCR are comparable to those calculated by SAM (Figure
2B).
Clorgyline induces genes suppressed by oncogenic 
pathways
The 156 genes identified by SAM as upregulated by clor-
gyline in E-CA-88 cells were compared to 12 oncogenic
pathway signatures compiled by Creighton [19]. Signifi-
cant subsets of the genes in these experimentally-derived
oncogenic signatures were shown to have coordinate
expression patterns in human prostate tumors [19]. For
instance, genes up-regulated experimentally by Myc, c-Src,
ERBB2, or Akt were co-expressed in at least three of four
different gene expression profile datasets of human PCa
(representing approximately 250 patients in all). More
then 50% of the genes selected by SAM as upregulated by
clorgyline treatment of E-CA-88 cells were downregulated
in at least one of the oncogenic pathways (Additional data
file 4). Genes downregulated by beta-catenin, Src, ERBB2,
Ras, E2F3, MEK, and Myc are significantly enriched in the
SAM list of clorgyline-induced genes by Chi-square test
(Table 1). These results suggest that clorgyline elicits an
anti-oncogenic transcriptional program in E-CA cells.
The oncogenic pathways regulated by beta-catenin, Src,
ERBB2, and Ras overlap and have common target genes.
For example, 1110 of the 1839 (60%) named genes
downregulated by beta-catenin as complied by Creighton
[19] are also downregulated by Src. Similarly, 595 (32%)
and 308 (17%) of genes downregulated by beta-catenin
are also downregulated by Ras and ERBB2, respectively
[19]. In our dataset, these genes downregulated in onco-
genic pathways are the most enriched in the SAM list of
clorgyline-induced genes and the enriched genes down-
regulated by beta-catenin, Src, Ras, and ERBB2 also over-
lap considerably. Specifically, 21, 19, and 12 out of the 36
genes (58%, 53%, and 33%) that overlap between beta-
catenin downregulated genes and the SAM list of clor-
gyline upregulated genes were also downregulated by Src,
Ras, and ERBB2, respectively.
Clorgyline induces APC and FAS expression and 
counteracts beta-catenin and ERBB2 pathways
Since APC is ranked as the 24th most significantly upregu-
lated gene by clorgyline in the SAM procedure, and it is a
well-known tumor suppressor that downregulates the
activity of the beta-catenin pathway through various
mechanisms [20], we validated its expression by qRT-
PCR. Consistent with the microarray data, APC is upregu-
lated 10-, 16-, and 12- fold at 6, 24, and 96 hr, respec-
tively, in clorgyline-treated cells compared to control
(Figure 3A). These results confirm that APC is strongly
upregulated in cancer cells by clorgyline. Another well-
studied key gene in cancer is the 50th gene on the SAM list,
FAS, a member of the TNF receptor superfamily. It has
been shown that FAS is downregulated by promoter
hypermethylation in PCa and is a potential biomarker
[21]. As shown in Figure 3A, FAS was upregulated 3.0-,
1.4-, and 2.7-fold by clorgyline as determined by qRT-PCR
at 6, 24, and 96 hr, respectively, consistent with our
microarray results.
To gain a comprehensive understanding of the effects of
clorgyline on the beta-catenin pathway, we compared
genes whose expression changed at least 2-fold in
response to clorgyline with beta-catenin pathway signa-
tures. Of the 1839 genes downregulated by beta-catenin,
564, 624, and 474 were up-regulated by clorgyline at 6,
24, and 96 hr, respectively, which is significantly enriched
(higher than expected by chance) as determined by Chi-
square test (Figure 3B and 3D). In addition, of the 934
genes upregulated by beta-catenin, 119, 191, and 56 were
Table 1: Comparison of genes identified by SAM with oncogenic pathway signatures*
Oncogenic pathway Number of unique genes down Number of genes overlap with 
SAM
Expected number of genes overlap 
with SAM
P-value
beta-catenin 1839 36 12 1.8E-12
Src 1944 37 13 3.7E-12
ERBB2 1350 26 9 3.8E-9
Ras 2224 35 14 4.1E-8
E2F3 1820 24 12 3.1E-4
MEK 1168 16 8 1.9E-3
Myc 1334 16 9 1.1E-2
*The named oncogenic pathway genes used for comparison were compiled by Creighton [19].BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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downregulated by clorgyline at 6, 24, and 96 hr, respec-
tively, which is also significantly enriched (Figure 3B and
3D). Moreover, genes upregulated by beta-catenin are sig-
nificantly anti-enriched (fewer than expected by chance)
in the lists of genes upregulated by clogyline at all three
time points (Figure 3D). Finally, although genes downreg-
ulated by beta-catenin showed enrichment at 6 and 24 hr
in the lists of genes downregulated by clorgyline, the
number is fewer than expected at 96 hr (Figure 3D). These
results suggest that, in large part, clorgyline induced a
transcriptional program that is inversely correlated with
beta-catenin pathway signatures. In other words, clor-
gyline seems to reverse the oncogenic pathway of beta-cat-
enin, perhaps through upregulation of APC.
Since APC is downregulated when ERBB2 is overexpressed
in breast cancer cells [22], we performed a similar analysis
to that described above to determine the effects of clor-
gyline treatment on ERBB2 pathway signatures. Of 1350
genes downregulated by ERBB2, 476, 604, and 328 were
Induction of APC and FAS expression and attenuation of beta-catenin and ERBB2 pathways by clorgyline in E-CA-88 cells Figure 3
Induction of APC and FAS expression and attenuation of beta-catenin and ERBB2 pathways by clorgyline in E-
CA-88 cells. (A) APC and FAS expression was increased by clorgyline at all three points of the time course determined by 
qRT-PCR. (B) Expression changes of genes in beta-catenin pathway signatures in response to clorgyline. (C) Expression 
changes of genes in ERBB2 pathway signatures in response to clorgyline treatment. For both (B) and (C), red indicates higher 
expression in treated vs. control E-CA-88 cells, and green indicates lower expression. Only changes ≥ 2-fold were displayed. 
The degree of color saturation corresponding to the fold change is shown at the bottom of the images. (D) Number of genes 
overlapping between those whose expression changed ≥ 2-fold after clorgyline treatment and beta-catenin pathway signature. 
(E) Number of genes overlapping between those whose expression changed ≥ 2-fold after clorgyline treatment and ERBB2 
pathway signature. For both (D) and (E), bars above the X-axis represent genes upregulated by clorgyline and bars below the 
X-axis downregulated. Asterisk indicates statistical significance by Chi-square test.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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upregulated in clorgyline-treated E-CA-88 cells at 6, 24,
and 96 hr, respectively, which is significantly enriched as
determined by Chi-square test (Figure 3C and 3E). In
addition, of the 1302 genes upregulated by ERBB2, 475,
222, and 55 were downregulated by clorgyline at 6, 24,
and 96 hr, respectively, which is also significantly
enriched (Figure 3C and 3E). Moreover, genes upregu-
lated by ERBB2 are significantly anti-enriched (fewer than
expected by chance) in the lists of genes upregulated by
clogyline at all three time points (Figure 3E). Finally,
genes downregulated by ERBB2 showed significant anti-
enrichment at 96 hr in the list of genes downregulated by
clorgyline (Figure 3E). These results demonstrate that
clorgyline induced genes that are suppressed by ERBB2
and repressed genes that are activated by ERBB2. There-
fore, similar to its effects on beta-catenin pathways, clor-
gyline reverses the transcriptional program induced by
ERBB2.
Clorgyline upregulates AR and modulates expression of 
androgen-regulated genes
We previously reported that clorgyline induces AR expres-
sion in normal prostatic epithelial cells [6]. In E-CA-88
cells, clorgyline also increases AR transcripts at 6 and 24 hr
by 1.4- and 3.6-fold, respectively [AR mRNA expression at
96 hr was not available after data filtering; however, AR
protein was detectable after 96 hr of clorgyline treatment
in E-CA cells (data not shown)]. In addition, PSA, a well
known AR target gene, showed increased expression at 6,
24, and 96 hr by 1.7-, 14.1-, and 9.8-fold, respectively.
These results suggest that clorgyline upregulates androgen
signaling in E-CA-88 cells. When compared with a list of
258 genes upregulated by androgen in LNCaP cells (an
immortal PCa cell line derived from a lymph node metas-
tasis which has mutated AR) that was generated by DeP-
rimo et al. [23], 69, 82, and 51 of these genes were also
upregulated in E-CA-88 cells by clorgyline at 6, 24, and 96
hr, respectively, representing a highly significant enrich-
ment by Chi-square test (Figure 4). Interestingly, a subset
of genes upregulated by androgen in LNCaP cells showed
decreased expression in response to clorgyline in E-CA-88
cells at 6 and 24 hr. The enrichment is statistically signifi-
cant although to a much lesser degree than for those that
are upregulated by clorgyline (Figure 4). Conversely, of
the 23 genes downregulated in LNCaP cells by androgen
that were identified by DePrimo et al., 9 and 14 were
upregulated by clorgyline in E-CA-88 cells at 6 and 24 hr,
respectively. These results suggest that clorgyline increases
androgen activity in E-CA cells, but with cell-specific
responses that may reflect differences in androgen signal-
ing between primary adenocarcinomas with wild-type AR
and metastatic cancers with mutated AR.
Clorgyline induces differentiation-related genes possibly 
through downregulation of EZH2
In normal prostatic epithelial cells, clorgyline induces the
expression of secretory epithelial cell markers including
AR and PSA and suppresses the expression of basal cell
markers such as cytokeratin 14. In E-CA-88 cells, clor-
gyline also induces secretory epithelial cell markers such
as AR, PSA, and PSMA as determined by qRT-PCR (Figure
5A), consistent with our microarray data. In addition,
clorgyline induces secretory epithelial cell-specific cell sur-
face antigens including CD6, CD2, and CD79B, and
Clorgyline treatment affected androgen signaling in E-CA-88 cells Figure 4
Clorgyline treatment affected androgen signaling in E-CA-88 cells. (A) Expression changes of androgen-regulated 
genes identified by DePrimo et al. in response to clorgyline treatment. Red indicates higher expression in treated vs. control E-
CA cells, and green indicates lower expression. Only changes ≥ 2-fold were displayed. The degree of color saturation corre-
sponding to the fold change is shown at the bottom of the image. (B) Number of genes whose expression changed ≥ 2-fold 
after clorgyline treatment found in the list of androgen-regulated genes. Bars above the X-axis represent genes upregulated by 
clorgyline and bars below the X-axis downregulated. Asterisk indicates statistical significance by Chi-square test.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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represses basal cell-specific cell surface antigens including
CD44, CD49B, and CD49C [24] (Table 2), suggesting that
clorgyline promotes secretory differentiation in PCa cells.
Consistent with these results, clorgyline-treated cells
showed significantly lower proliferation capacity com-
pared to control cells (Figure 5B).
The Polycomb Group (PcG) protein EZH2 is a critical
component of a multiprotein complex that represses the
expression of genes involved in differentiation [25]. EZH2
overexpression is associated with high grade and meta-
static PCa and is a risk factor for progression [26]. By qRT-
PCR, transcript levels of EZH2 did not show significant
changes in response to clorgyline at 6 and 96 hr; however,
EZH2 mRNA was decreased by 32% at 24 hr in clorgyline-
treated cells (Figure 6A). Moreover, expression of ADRB2,
a direct target of EZH2 [27], was concurrently increased by
50%. Both EZH2 and ADRB2 expression changes were sta-
tistically significant by student's t-test. ADRB2 was also
upregulated by clorgyline in our microarray data (2.1 and
1.7 fold at 6 and 24 hr, respectively; data for 96 hr was not
available after filtering), although EZH2 expression
showed minimal increase (1.0-, 1.2-, and 1.2- fold at 6,
24, and 96 hr, respectively).
To systematically examine the effect of clorgyline on
EZH2 targets, we compared genes whose expression
changed by 2-fold or more in response to clorgyline with
a Polycomb repression signature consisting of 87 PcG-
occupied genes that has been shown to predict patient
survival in PCa [28]. Of these 87 genes, 23, 29, and 10
were upregulated by clorgyline at 6, 24, and 96 hr, respec-
tively (Figure 6B). The enrichment of this Polycomb
repression signature in genes upregulated by clorgyline is
statistically significant at 6 and 24 hr. In addition, 13 of
these PcG-repressed genes were upregulated at both 6 and
24 hr, demonstrating a consistent upregulation of a subset
of the Polycomb repression signature by clorgyline.
We attempted to validate four Polycomb signature genes
that have been implicated in the differentiation of various
cell types, namely MYO6, SATB2, SOCS2, and RGC32, by
qRT-PCR [29-32]. As shown in Figure 6A, expression of
three of the four genes was significantly upregulated in
treated E-CA-88 cells compared to control, suggesting that
clorgyline induced genes suppressed by the Polycomb
complex. Taken together, these results suggest that down-
regulation of EZH2 and reversal of repression of its target
genes may play a role in clorgyline-induced differentia-
tion.
Validation of the effects of clorgyline using E-CA-90 cells
To validate the effects of clorgyline on E-CA cells, we
treated E-CA-90 cells derived from another Gleason grade
4 cancer as for E-CA-88 and measured the expression of
selected genes by qRT-PCR. As shown in Figure 7A, all of
the top 10 genes in the SAM list generated from E-CA-88
cells were also significantly upregulated in E-CA-90 cells
after 24 hr of clorgyline treatment. At 96 hr, 7 of the 10
top SAM genes were significantly upregulated in E-CA-90
cells. In addition, both APC and FAS, the 24th and 50th
SAM genes, respectively, were significantly upregulated at
24 and 96 hr. Moreover, secretory cell markers including
AR, PSA, and PSMA were induced at both time points.
Finally, three of the four Polycomb signature genes,
MYO6, SOCS2, and SATB2, were significantly upregulated
in clorgyline-treated E-CA-90 cells compared to control by
3.6-, 3.7-, and 2.6-fold, respectively, while EZH2 was
downregulated by 40% at 24 hr. These results suggest that
clorgyline induced genes suppressed by the Polycomb
complex in E-CA-90 cells. Consistent with the notion that
secretory differentiation was induced by clorgyline, the
proliferation potential of treated E-CA-90 cells was dra-
matically decreased compared to control (Figure 7B), sim-
ilar to treated E-CA-88 cells. These results suggest that the
effects of clorgyline on primary E-CA cells from high grade
cancer are reproducible and generalizable.
Table 2: Expression change of cell type specific cell surface antigens in response to clorglyine
Expression change
Cell surface antigen Cell type expression 6 hr 24 hr
CD6 luminal ↑3.1 ↑2.3
CD79B luminal ↑2.7 NA
CD24 luminal NA ↑3.6
CD44 basal ↓4.7 ↓6.6
CD49B basal NA ↓2,1
CD49C basal ↓6.3 ↓6.7BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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Clorgyline induced expression of secretory differentiation markers and decreased the proliferation capacity of E-CA-88 cells Figure 5
Clorgyline induced expression of secretory differentiation markers and decreased the proliferation capacity of 
E-CA-88 cells. (A) Expression of AR, PSA, and PSMA, three well-known secretory cell markers, were upregulated by clor-
gyline in E-CA-88 cells as determined by qRT-PCR. (B) The proliferation capacity of E-CA-88 cells was significantly decreased 
after 6, 24, and 96 hr of clorgyline-treatment compared to control cells. For both (A) and (B), asterisk indicates statistical sig-
nificance by t-test.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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Clorgyline downregulated EZH2 and upregulated its target genes in E-CA-88 cells Figure 6
Clorgyline downregulated EZH2 and upregulated its target genes in E-CA-88 cells. (A) Expression of EZH2 was 
decreased and its target, ADRB2, was increased at 24 hr after clorgyline treatment as determined by qRT-PCR. Expression of 
3 of 4 PcG signature genes was upregulated in clorgyline-treated cells compared to control as determined by qRT-PCR. (B) 
Expression of PcG signature genes was upregulated after clorgyline treatment at 6 and 24 hr as determined by microarray. 
Asterisks indicate genes upregulated at both 6 and 24 hr.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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Clorgyline induced similar changes in gene expression and proliferation in E-CA-90 cells Figure 7
Clorgyline induced similar changes in gene expression and proliferation in E-CA-90 cells. (A) Expression of the 
top 10 SAM genes in E-CA-88 cells was upregulated at 24 and 96 hr after clorgyline treatment of E-CA-90 cells with some 
exceptions (arrowheads), as determined by qRT-PCR. Similarly, expression of APC and FAS as well as AR, PSA, and PSMA, 
three well-known secretory cell markers, was upregulated by clorgyline in E-CA-90 cells. (B) The proliferation capacity of E-
CA-90 cells was significantly decreased after 6, 24, and 96 hr of clorgyline treatment as compared to control cells. For both (A) 
and (B), asterisk indicates statistical significance by t-test.BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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Discussion
We systematically assessed gene expression changes
induced by the MAO-A – specific inhibitor, clorgyline, in
primary cultures of prostatic epithelial cells from high
grade cancer. SAM identified 156 unique named genes
whose expression was significantly upregulated by clor-
gyline across all three time points (6 – 96 hrs) tested in
this study. Strikingly, more than half of these genes are
reportedly suppressed by at least one known oncogene
(beta-catenin, Src, ERBB2, Ras, E2F3, MEK and Myc) [19],
suggesting an anti-oncogenic effect of clorgyline. For
example, SAMD9, the gene most significantly upregulated
by clorgyline, is repressed in a variety of neoplasms asso-
ciated with beta-catenin stabilization [33]. Knockdown of
SAMD9 increased the proliferation and invasiveness of
cancer cells, whereas SAMD9 overexpression reduced cell
proliferation and motility [33]. In addition, SAMD9
expression was dramatically increased in an aggressive
fibromatosis tumor with inactivation of the APC gene
after transfection of wild type APC [33]. In our data set,
APC is the 24th most significantly upregulated gene by
clorgyline, indicating a possible regulation of SAMD9 by
APC in E-CA cells.
When considering genes up- and -downregulated by at
least 2-fold at individual time points, it is clear that clor-
gyline elicits an extensive anti-oncogenic effect in E-CA
cells. Specifically, clorgyline repressed oncogene-activated
gene expression and induced oncogene-suppressed gene
expression in E-CA cells, which was observed consistently
across all time points. Moreover, this attenuation is effec-
tive on multiple oncogenic pathways. Such a broad spec-
trum counteracting role of a single agent on multiple
oncogenic pathway activities has not been reported. It is
well known that the development and progression of PCa
involves the activation of oncogenic pathways. For exam-
ple, mutations and alterations in expression pattern of
beta-catenin have been detected in PCa samples and in
some studies were correlated with Gleason grade [34,35].
Another oncogene, ERBB2, was found overexpressed in
PCa with an increasing incidence from localized to meta-
static disease [36]. ERBB2 may also play a role in the pro-
gression of PCa from androgen-dependent to -
independent [36]. Given the importance of these onco-
genic pathways in PCa development and progression, an
anti-oncogenic agent that counteracts multiple pathways
may be an effective therapeutic drug against PCa.
Clorgyline also has a major effect on androgen signaling
in E-CA cells by upregulating AR as well as classic AR target
genes such as PSA and PSMA. The overall pattern of
androgen-related gene expression changes in E-CA cells
possibly reflects cell-specific activity. For example, clor-
gyline treatment of E-CA cells upregulated a set of andro-
gen-induced genes at all three time points that were also
upregulated by androgen in LNCaP cells in the study by
DiPrimo et al. [23]. Meanwhile, other sets of androgen-
regulated genes were increased in LNCaP cells by andro-
gen and decreased in E-CA cells by clorgyline, or vice
versa. Similarly, comparison with another published list
of genes regulated by androgen in LNCaP cells engineered
to overexpress wild type AR (LNCaP-AR) revealed similar-
ities and differences to responses of the parental LNCaP
cells themselves as well as to E-CA cells [37]. Cell-specific
responses to hormones are well-documented and are due
to a number of factors, including the repertoire of co-reg-
ulators available in each type of cell [38,39].
Whether increased expression of AR and androgen signal-
ing in a high grade primary adenocarcinoma would be
clinically beneficial or detrimental is a subject of debate.
On the one hand, androgen can promote prostatic differ-
entiation [40]. Classic androgen withdrawal and repletion
experiments in rodents have suggested that androgen
functions primarily to maintain the homeostasis of differ-
entiated luminal epithelial cells [41,42]. Recent molecular
studies have shown that, in addition to the well-character-
ized androgen-regulated genes such as PSA, many addi-
tional androgen-regulated genes are predicted to be
secreted proteins, or play a role in prostate secretory func-
tion [23]. From this point of view, upregulation of andro-
gen signaling may be anti-oncogenic by promoting
differentiation of PCa cells. This idea is supported by the
work of Berger et al. using immortalized and tumorigenic
human prostatic epithelial cells, in which introduction of
AR induced differentiation of these cells to a secretory
phenotype reminiscent of organ-confined PCa [43]. How-
ever, caution needs to be taken when drawing conclusions
from these cell lines because the genetic makeup of these
cells has been altered during establishment and long-term
propagation, and AR was introduced exogenously. In con-
trast, our primary cultured cells are not genetically manip-
ulated and will provide new insights into androgen-
regulated differentiation in PCa.
On the other hand, AR-mediated androgen signaling may
be oncogenic. For example, elevated AR expression is
thought to contribute to the progression of PCa from
androgen-sensitive to androgen-insensitive. Most so-
called "androgen-insensitive" prostate cancers in fact
retain high levels of AR expression [44] and PSA continues
to be expressed [45]. In PCa xenografts, an increase in AR
mRNA and protein was both necessary and sufficient to
convert growth from a hormone-sensitive to a hormone-
refractory stage [37], while knocking down AR reduced
cell growth in both androgen-sensitive and -insensitive
cancer cells [46]. Therefore, counteracting AR-mediated
androgen signaling in PCa may prevent progression of the
disease. Because clorgyline induced a subset of androgen-
regulated genes while repressing others, it is possible that
clorgyline counteracts androgen-mediated tumor prolifer-BMC Medical Genomics 2009, 2:55 http://www.biomedcentral.com/1755-8794/2/55
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ation while promoting tumor-repressing, androgen-medi-
ated differentiation.
In conjunction with induction of AR, the quintessential
marker of differentiated prostatic secretory epithelial cells,
clorgyline induced other genes associated with secretory
differentiation and repressed genes associated with a basal
cell phenotype. Although preliminary, some evidence
from this study suggests that induction of differentiation
upon clorgyline treatment might be mediated through
downregulation of EZH2. At 24 hr, EZH2 was significantly
downregulated by clorgyline while genes known to be
repressed by EZH2, such as ADRB2, were upregulated as
determined by qRT-PCR. Moreover, a significant enrich-
ment of genes repressed by the Polycomb protein com-
plex (consisting of EZH2 and two other partners) in
clorgyline-upregulated genes supports this possibility.
Expression of this Polycomb repression signature is asso-
ciated with poor prognosis in multiple PCa datasets [28],
suggesting that clorgyline may improve patient outcome
through upregulation of Polycomb protein complex
repressed genes.
Conclusion
We identified two major effects of clorgyline in high grade
PCa cells, namely anti-oncogenesis and pro-differentia-
tion. Our results suggest novel therapeutic applications
against PCa of antidepressant drugs that target MAO-A.
Additional studies are needed to determine whether
induction of differentiation and inhibition of oncogenic
signaling pathways in high grade primary adenocarcino-
mas of the prostate would prevent progression to meta-
static disease and death, and to investigate the expression
and function of MAO-A in metastatic and/or androgen-
refractory PCa.
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